Expand BIIB Menu
BIIB MENU

BIIB Latest Press Releases

-- December 12, 2025 --

Annual Changes to the Nasdaq-100 Index Globe Newswire 8:00 PM

-- December 8, 2025 --

"LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List Globe Newswire 6:30 PM

-- December 5, 2025 --

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting Business Wire 9:00 AM
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting Globe Newswire 9:00 AM

-- December 3, 2025 --

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 PRNewswire 6:10 PM
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Globe Newswire 6:10 PM

-- December 2, 2025 --

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic A Protofibrils in CSF PRNewswire 4:40 PM
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic A Protofibrils in CSF Globe Newswire 4:40 PM

-- December 1, 2025 --

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting Globe Newswire 7:30 AM
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting Business Wire 7:30 AM

-- November 27, 2025 --

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI" for the Treatment of Early Alzheimer's Disease in Japan Globe Newswire 7:30 PM

-- November 25, 2025 --

Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status PRNewswire 7:30 AM
Eisai Completes Rolling Submission to US FDA for LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status Globe Newswire 7:30 AM

-- November 24, 2025 --

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions Globe Newswire 7:30 AM

-- November 20, 2025 --

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference Globe Newswire 7:30 AM

-- November 17, 2025 --

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments Business Wire 7:30 AM
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments Globe Newswire 7:30 AM
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy Globe Newswire 6:00 AM

-- November 14, 2025 --

Biogen Completes Acquisition of Alcyone Therapeutics Globe Newswire 4:05 PM

-- November 13, 2025 --

"LEQEMBI" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom Globe Newswire 6:30 PM

-- November 3, 2025 --

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025 Globe Newswire 7:30 AM

-- October 26, 2025 --

Health Canada Grants Authorization for "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Globe Newswire 7:30 PM

-- October 24, 2025 --

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio Globe Newswire 7:30 AM

-- October 22, 2025 --

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 Globe Newswire 7:30 AM

-- October 13, 2025 --

LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" PRNewswire 7:30 PM
LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" Globe Newswire 7:30 PM

-- October 10, 2025 --

/C O R R E C T I O N -- National Association of Corporate Directors/ PRNewswire 6:25 PM
Global Leaders Jess Mantas and Wes Bricker Join NACD Board of Directors PRNewswire 10:01 AM

-- October 9, 2025 --

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome Business Wire 4:30 PM
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome Globe Newswire 4:30 PM

-- October 6, 2025 --

Eisai and Biogen Announce U.S. Availability of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease PRNewswire 4:30 PM
Eisai and Biogen Announce U.S. Availability of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease Globe Newswire 4:30 PM

-- September 28, 2025 --

"LEQEMBI" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China Globe Newswire 7:30 PM

-- September 24, 2025 --

LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia Globe Newswire 7:30 AM

-- September 23, 2025 --

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen Globe Newswire 4:30 PM

-- September 18, 2025 --

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates Globe Newswire 7:40 AM

-- September 17, 2025 --

Biogen Receives European Commission Approval for ZURZUVAE (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe Globe Newswire 4:30 PM

-- September 2, 2025 --

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status ACN Newswire 10:56 PM
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status Globe Newswire 7:30 PM
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status PRNewswire 7:30 PM
/U P D A T E -- Eisai Inc./ PRNewswire 3:58 PM
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome Business Wire 7:00 AM
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome Globe Newswire 7:00 AM

-- September 1, 2025 --

FDA Approves LEQEMBI® IQLIKTM (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease ACN Newswire 12:50 AM

-- August 29, 2025 --

FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease PRNewswire 5:00 PM
FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease Globe Newswire 5:00 PM

-- August 25, 2025 --

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress Business Wire 7:00 AM
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress Globe Newswire 7:00 AM
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) ACN Newswire 6:57 AM
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI (lecanemab) Globe Newswire 3:00 AM

-- August 13, 2025 --

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 7:20 PM

-- August 11, 2025 --

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome Business Wire 7:00 AM
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome Globe Newswire 7:00 AM

-- July 30, 2025 --

Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC ACN Newswire 11:19 PM
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease ACN Newswire 10:40 PM
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 ACN Newswire 9:48 PM
Two-Year Real-World Study of LEQEMBI in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 PRNewswire 11:00 AM
Two-Year Real-World Study of LEQEMBI in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 Globe Newswire 11:00 AM
New Data Presented at AAIC Demonstrates Investigational LEQEMBI (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease PRNewswire 9:00 AM
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC PRNewswire 8:07 AM
Market Data Delayed 15 Minutes